Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Combined medicine with synergistic action for treating T cell lymphomata and application thereof

A synergistic, lymphoma technology, used in drug combinations, antineoplastic drugs, active ingredients of amides, etc., which can solve the problem of less than 30% survival rate, easy relapse of patients, and unclear efficacy and possible mechanism of T-cell lymphoma. and other problems to achieve the effect of reducing costs, improving efficacy, and overcoming drug resistance

Inactive Publication Date: 2010-06-16
RUIJIN HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE
View PDF0 Cites 8 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The treatment of T-cell lymphoma is still based on combination chemotherapy, patients are prone to relapse, and the overall 5-year survival rate is less than 30%.
However, the efficacy and possible mechanisms of their combined use against T-cell lymphoma remain poorly understood

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Combined medicine with synergistic action for treating T cell lymphomata and application thereof
  • Combined medicine with synergistic action for treating T cell lymphomata and application thereof
  • Combined medicine with synergistic action for treating T cell lymphomata and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0030] (1) Reagents

[0031] Bortezomib (Bortezomib, purchased from Millennium Pharmaceuticals) was stored at 2.6 mM in stock solution and stored at 4°C; SAHA (a gift from Merck) was dissolved in DMSO at 100 mM stock solution and stored at -20°C. MTT, propidium iodide (PI), rhodamine 123 (Rho123), dithiothreitol (DTT), protease inhibitor complex, GAPDH monoclonal antibody were purchased from Sigma; Annexin V / PI apoptosis detection kit Purchased from BD Company; P27, NF-κB (P65), Lamin B, IκB α, Raf-1, MEKK-1, MEKK-2, C-myc antibody, horseradish peroxidase-coupled goat anti-mouse II Anti-goat anti-rabbit secondary antibody, rabbit anti-goat secondary antibody was purchased from Santa Cruz Company; TUNEL tissue specimen apoptosis detection kit was purchased from Promega Company; Caspase-8, Caspase-9, Caspase-3, P21, phosphorylated IKKα / β, IKKα antibody, phosphorylated MEK, MEK, phosphorylated ERK1 / 2, ERK1 / 2, phosphorylated AKT, AKT, phosphorylated JNK1 / 2, JNK1 / 2, phosphorylate...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
thicknessaaaaaaaaaa
Login to View More

Abstract

The invention relates to a combined medicine with a synergistic action for treating T cell lymphomata. The combined medicine comprises bortezomib and SAHA, wherein the proportion of the bortezomib to the SAHA is 5-10nM:1-2.0 mu M. The invention also provides an application of the combined medicine in preparing a medicine for treating lymphomata diseases, wherein the lymphomata is T cell lymphomata. By using the combined medicine, the synergistic action of the two medicines is exerted, and the growth and the multiplication of T lymphomata cells can be synergically suppressed. By combining the two medicines, the curative effect is enhanced, and the cost can also be greatly lowered.

Description

【Technical field】 [0001] The invention relates to a medicine for treating cancer, in particular to a combined medicine with synergistic effect for treating T-cell lymphoma and application thereof. 【Background technique】 [0002] Lymphoma is a malignant tumor that originates in lymph nodes or extranodal lymphoid tissues. It is divided into Hodgkin's lymphoma and non-Hodgkin's lymphoma, of which non-Hodgkin's lymphoma accounts for about 70-80%. There are approximately 350,000 new cases and more than 200,000 deaths worldwide each year. In my country, the current incidence of lymphoma is about 3-4 / 100,000, accounting for the 9th among malignant tumors, and the 11th in the death rate of malignant tumors, accounting for 4.8% of all cancer deaths. Second only to acute leukemia. [0003] Non-Hodgkin's lymphoma can be divided into B-cell lymphoma and T-cell lymphoma. In my country, the incidence of T-cell lymphoma is much higher than that in European and American countries, accounti...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/69A61K38/05A61K31/16A61P35/00
Inventor 赵维莅陈赛娟张群岭王黎张轶文姜晓星
Owner RUIJIN HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com